ARCHIVES

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

October 7, 1977

Kennedy Agrees To Drop Dollar Limit In New Cancer Bill

January 11, 1980

Research Regulation: NRC fines NIH for Not Securing Radioactive Materials

September 13, 1996

NCI Programs: BSA Approves concept For Grants Program In Statistical Modeling

July 16, 1999

NCI Role, Issues In Education Considered By DRCCA Board

August 21, 1981

Dendreon’s Provenge Approved For Prostate Cancer Treatment

April 30, 2010